[go: up one dir, main page]

AU2905199A - Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject - Google Patents

Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject

Info

Publication number
AU2905199A
AU2905199A AU29051/99A AU2905199A AU2905199A AU 2905199 A AU2905199 A AU 2905199A AU 29051/99 A AU29051/99 A AU 29051/99A AU 2905199 A AU2905199 A AU 2905199A AU 2905199 A AU2905199 A AU 2905199A
Authority
AU
Australia
Prior art keywords
subject
tumor cells
chemotherapeutic agent
oncolytic virus
combined therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29051/99A
Inventor
Larry Kaiser
Katherine Molnar-Kimber
Takane Toyoizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2905199A publication Critical patent/AU2905199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/763Herpes virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/766Rhabdovirus, e.g. vesicular stomatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU29051/99A 1999-03-15 1999-03-15 Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject Abandoned AU2905199A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/005536 WO2000054795A1 (en) 1999-03-15 1999-03-15 Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject

Publications (1)

Publication Number Publication Date
AU2905199A true AU2905199A (en) 2000-10-04

Family

ID=22272350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29051/99A Abandoned AU2905199A (en) 1999-03-15 1999-03-15 Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject

Country Status (2)

Country Link
AU (1) AU2905199A (en)
WO (1) WO2000054795A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
MXPA01010393A (en) 1999-04-15 2004-04-02 Pro Virus Inc Treatment of neoplasms with viruses.
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
NO20014256D0 (en) 2001-09-03 2001-09-03 Bjoern Kristiansen Preparation of immunostimulatory compound
KR20070008710A (en) * 2004-04-27 2007-01-17 웰스테트 바이올로직스 코포레이션 Cancer treatment method using virus and camptothecin
US7514085B2 (en) 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
EP1896600A2 (en) 2005-06-15 2008-03-12 Medimush A/S Anti-cancer combination treatment and kit-of-part
CN102124335B (en) * 2008-05-22 2014-07-30 第一药品株式会社 Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
ES2704848T3 (en) * 2011-10-12 2019-03-20 Sbi Pharmaceuticals Co Ltd Treatment agent and / or prophylactic agent for side effects of cancer drugs
EP2662117A1 (en) * 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus for the treatment of liver cancer
KR20230107375A (en) 2014-12-18 2023-07-14 암젠 인크 Stable frozen herpes simplex virus formulation
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
JP2020510050A (en) 2017-03-15 2020-04-02 アムジエン・インコーポレーテツド Use of an oncolytic virus alone or in combination with a checkpoint inhibitor to treat cancer
TW201900193A (en) 2017-04-28 2019-01-01 美商默沙東藥廠 Biomarkers for cancer treatment
SI3661954T1 (en) 2017-08-03 2022-05-31 Amgen Inc. Interleukin-21 muteins and treatment procedures
TW201912173A (en) 2017-08-07 2019-04-01 美商安進公司 Treatment of triple-negative breast cancer or colorectal cancer with liver metastasis
ES2985118T3 (en) 2017-09-08 2024-11-04 Amgen Inc KRAS G12C inhibitors and methods of using them
UY38049A (en) 2018-01-12 2019-07-31 Amgen Inc ANTI-PD-1 ANTIBODIES AND TREATMENT METHODS
WO2019168346A1 (en) * 2018-02-28 2019-09-06 주식회사 바이오녹스 Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components
MX2021007639A (en) 2018-12-27 2021-08-11 Amgen Inc Lyophilized virus formulations.
US20220090133A1 (en) 2019-03-05 2022-03-24 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
TW202102543A (en) 2019-03-29 2021-01-16 美商安進公司 Use of oncolytic viruses in the neoadjuvant therapy of cancer
JP7326663B2 (en) * 2019-08-26 2023-08-16 バイオノックス インコーポレイテッド Pharmaceutical composition containing vaccinia virus and hydroxyurea as active ingredients for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Also Published As

Publication number Publication date
WO2000054795A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
AU2905199A (en) Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
AU2001228205A1 (en) Linac neutron therapy and imaging
AU3957600A (en) Piperidyl-imidazole derivatives, their preparations and therapeutic uses
ZA979096B (en) Viral and cancer treatment
AU7459600A (en) Smooth muscle cell promoter and uses thereof
AU2736101A (en) Transporters and ion channels
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
AU2868999A (en) Improvements in wheeled luggage and associated devices
AU715620C (en) Therapeutic methods and uses
AU9633098A (en) Benzoxazine derivatives, preparation and application in therapy
AU2002232925A1 (en) Air-flow containment and distribution assembly
AU5918098A (en) Non-immunogenic prodrugs and selectable markers for use in gene therapy
AU2452197A (en) Genes amplified in cancer cells
AU2001266229A1 (en) Hcn polypeptides and polynucleotides and their use in therapy
AU9269898A (en) Artificial viruses derived from papillomavirus, and their uses, in particular gene therapy
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
IL133536A0 (en) 6-pyrrolidin-2-ylpyridine derivatives, their preparation and application in therapy
AU2383300A (en) Diagonal toy pieces and their connection
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
AU5764399A (en) Antigen-presenting cells and their use in therapy
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
AU4860299A (en) (zap-3) tumor associated genes and their uses
AU6924198A (en) Benzenesulphonamide derivatives, preparation and application thereof in therapy
AU6149600A (en) Novel vector complexes and their use in gene therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase